HYPERDIAMOND ("Molecular Imaging via Hyperpolarized Nanodiamonds") is a European collaborative research and innovation project led by a multi-disciplinary consortium coordinated by Ulm University.
The objective of HYPERDIAMOND is the development of two new molecular imaging technologies for MRI medical imaging enabling sensitive diagnosis and treatment monitoring based on novel quantum and nanotechnology.
The HYPERDIAMOND Consortium involves 10 partners from three EU member states (Germany, France, Austria) and EU Associated Countries Israel and Switzerland and includes 3 SME’s. The project partners have a long history of successful collaboration in research and innovation projects. Altogether, they build a multidisciplinary team with leading expertise in molecular imaging, nuclear magnetic resonance (NMR), nanodiamond material science, theoretical and experimental physics in quantum technologies, diamond surface bio-chemistry, small animal magnetic resonance imaging (MRI), pre-clinical expertise and medical devices and magnetics production.
The HYPERDIAMOND consortium, through its combination of renowned research institutes and innovative small enterprises, unites all relevant expertise to reach the ambitious objectives of the project to develop and commercialise the two platforms for MRI-based molecular imaging.
HYPERDIAMOND is supported by the European Commission under the HORIZON 2020 European Union funding for Research and Innovation, Grant Agreement number 667192. With a project budget of 5M€ the project is implemented during 4 years (2016-2019).
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 667192
